Symmetry Partners 13F: Adds $1M to Johnson & Johnson (JNJ) Stake
Key Points
- Symmetry Partners increased its holdings in Johnson & Johnson by 3,909 shares, raising its total to 12,406 shares, which represents a 46.0% increase in this position.
- The stock closed at $268.73 on October 27, 2026, and recently traded around $268.78, which is about equal to the closing price.
- Johnson & Johnson has a market cap of approximately $641 billion and a forward P/E ratio of 22.9, indicating a solid valuation in the healthcare sector.
Get Johnson & Johnson text alerts
We text you when insiders, Congress, analysts or big funds move on $JNJ.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Johnson & Johnson alert may contain errors. Disclosures
On October 27, 2026, Symmetry Partners boosted its position in Johnson & Johnson (NYSE: JNJ) by 3,909 shares, increasing its total holdings to 12,406 shares valued at about $3.28 million. This change was reported in the fund's latest Form 13F filing with the SEC.
JNJ
Johnson & Johnson
Where Johnson & Johnson Fits in Symmetry Partners' Portfolio
Symmetry Partners' stake in Johnson & Johnson now accounts for 0.64% of its total portfolio, ranking 20th among its 358 reported positions. The fund's reported total value stands at approximately $515.5 million.
Other Institutional Activity in Johnson & Johnson
Indivisible Partners grew its stake in Johnson & Johnson by 16,932 shares, bringing its total to 42,233 shares valued at about $11.2 million. Meanwhile, Signaturefd added 4,917 shares, increasing its holdings to 77,490 shares worth approximately $20.5 million. Ag2R la Mondiale Gestion D'Actifs reduced its position by 13,849 shares, leaving it with 128,512 shares valued at around $34 million.
Johnson & Johnson Stock Up 1.9%
Johnson & Johnson's shares closed at $268.73 on October 27, 2026. As of October 28, 2026, the stock was recently trading around $268.78, which is about equal to its closing price. The stock is currently above its 200-day moving average by 9.4% and above its 50-day moving average by 1.3%.
Recent Earnings
In its most recent earnings report, Johnson & Johnson reported trailing twelve-month revenue of approximately $99.3 billion and earnings per share (EPS) of $6.59. The next earnings date is scheduled for January 26, 2027.
Dividend
Johnson & Johnson pays an annual dividend rate of $5.36 per share, resulting in a yield of about 2.01%. The dividend payout ratio is approximately 80.1%.
Insider Buying and Selling at Johnson & Johnson
Several insiders have sold shares recently, including Elizabeth Forminard, who sold 15,918 shares on August 6, 2026, and Joaquin Boix Duato, who sold 123,291 shares on August 13, 2026. Jennifer L Taubert and Timothy Schmid also sold shares on August 17 and September 2, 2026, respectively.
Analysts Set New Price Targets
On October 14, 2026, several firms maintained their ratings on Johnson & Johnson, including Leerink Partners, which rates it as Outperform with a price target of $272. Wells Fargo also maintained an Overweight rating with a target of $275. The consensus recommendation for the stock remains a buy, with a mean price target of approximately $279.41.
About Johnson & Johnson
Johnson & Johnson, headquartered in New Brunswick, NJ, is a healthcare company that researches, develops, manufactures, and sells a wide range of products. Its operations are divided into two segments: Innovative Medicine and MedTech. This position boost by Symmetry Partners highlights the firm's confidence in Johnson & Johnson's growth potential.
Bottom Line
Investors should watch for Johnson & Johnson's next earnings report on January 26, 2027. Symmetry Partners' increased stake in the company reflects its strategic investment decisions, while other institutional activities indicate a broader interest in this healthcare giant.
Related Filing Alerts
Source: Symmetry Partners's 13F filing on $JNJ (Oct 27, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts